A Phase 1 interventional study of Single dose of PF-07104091 as Tablet Formulation A (Treatment A) and Single dose of PF-07104091 as Tablet Formulation B (Treatment B) in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-08.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single dose crossover pharmacokinetic (pharmacokinetics helps in understanding how the drug is changed and eliminated from the body after a participant takes it) study in healthy participants. The study consists of 5 treatments, and each participant will be randomized to receive 4 of the treatments in separate periods in a specific sequence. Each treatment consists of a single dose of PF-07104091 and the treatments differ by tablet formulation and/or whether the dose is to be given under fasted or fed conditions. Plasma pharmacokinetics of PF-07104091 will be assessed following each dose to determine the effect of tablet formulation and fed condition on the relative bioavailability of PF-07104091.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Also known as: Tablet Formulation A, Fasted
A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Also known as: Tablet Formulation B, Fasted
A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Also known as: Tablet Formulation C, Fasted
A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Also known as: Tablet Formulation D, Fasted
A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Also known as: Tablet Formulation C, Fed
Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C
AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.
Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C
Cmax was maximum observed concentration. Cmax was observed directly from data.
Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
AUCinf of PF-07104091 for Treatment C, D and E
AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.
Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Cmax of PF-07104091 for Treatment C, D and E
Cmax was maximum observed concentration. Cmax was observed directly from data.
Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, other important medical events. TEAEs were defined as events that occurred after start of treatment.
Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Number of Participants With Laboratory Test Abnormalities
Clinical hematology parameters included: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry parameters included: blood urea nitrogen and creatinine, cystatin C and estimated glomerular filtration rate, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, urinalysis parameters included: local dipstick: potential of hydrogen (pH), glucose, protein, blood, ketones, nitrites, leukocyte esterase. Number of participants with abnormal findings are presented in this outcome measure.
Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Number of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments
A 12-lead ECG was performed. Clinically meaningful findings in ECG assessments were based on the investigator's judgment.
Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Number of Participants With Clinically Meaningful Findings in Vital Signs
Vital signs were measured with the participant's arm supported at the level of the heart after approximately 5 minutes of rest. Vital signs parameters included: diastolic and systolic blood pressure, respiratory rate, pulse rate, and temperature. Number of participants with clinically meaningful findings in any vital sign parameter were reported. Clinically meaningful findings were based on the investigator's judgment.
Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Number of Participants With Clinically Meaningful Findings in Physical Examination Assessments
A complete physical examination included at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms. Clinically significant findings were defined according to investigator's assessment.
Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ABCD | Treatment Sequence BCAD | Treatment Sequence CABD | Treatment Sequence ABCE | Treatment Sequence BCAE | Treatment Sequence CABE |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 5 |
| Completed | 5 | 5 | 5 | 5 | 4 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.
| Nanograms*hour per milliliter | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) |
|---|---|---|---|
| Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C | 10920 ± 34 | 10720 ± 28 | 11200 ± 32 |
Cmax was maximum observed concentration. Cmax was observed directly from data.
| Nanograms per milliliter | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C | 1531 ± 31 | 1490 ± 28 | 1415 ± 34 |
AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.
| Nanograms*hour per milliliter | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|
| AUCinf of PF-07104091 for Treatment C, D and E | 11200 ± 32 | 12850 ± 32 | 10500 ± 24 |
Cmax was maximum observed concentration. Cmax was observed directly from data.
| Nanograms per milliliter | Treatment C: PF-07104091 Tablet Formulation (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|
| Cmax of PF-07104091 for Treatment C, D and E | 1415 ± 34 | 1498 ± 36 | 1193 ± 36 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, other important medical events. TEAEs were defined as events that occurred after start of treatment.
| Participants | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| TEAEs | 21 | 19 | 17 | 7 | 2 |
| Serious TEAEs | 0 | 0 | 0 | 0 | 0 |
Clinical hematology parameters included: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry parameters included: blood urea nitrogen and creatinine, cystatin C and estimated glomerular filtration rate, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, urinalysis parameters included: local dipstick: potential of hydrogen (pH), glucose, protein, blood, ketones, nitrites, leukocyte esterase. Number of participants with abnormal findings are presented in this outcome measure.
| Participants | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 0 | 0 | 1 | 3 | 1 |
A 12-lead ECG was performed. Clinically meaningful findings in ECG assessments were based on the investigator's judgment.
| Participants | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments | 0 | 0 | 0 | 0 | 0 |
Vital signs were measured with the participant's arm supported at the level of the heart after approximately 5 minutes of rest. Vital signs parameters included: diastolic and systolic blood pressure, respiratory rate, pulse rate, and temperature. Number of participants with clinically meaningful findings in any vital sign parameter were reported. Clinically meaningful findings were based on the investigator's judgment.
| Participants | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Findings in Vital Signs | 0 | 0 | 0 | 0 | 0 |
A complete physical examination included at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms. Clinically significant findings were defined according to investigator's assessment.
| Participants | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Findings in Physical Examination Assessments | 0 | 0 | 0 | 0 | 0 |
Collected over From start of study treatment until 35 days after last dose of study treatment (Up to Day 54). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: PF-07104091 Tablet Formulation A (Fasted) | 0/29 (0%) | 0/29 (0%) | 21/29 (72.4%) |
| Treatment B: PF-07104091 Tablet Formulation B (Fasted) | 0/30 (0%) | 0/30 (0%) | 18/30 (60%) |
| Treatment C: PF-07104091 Tablet Formulation C (Fasted) | 0/29 (0%) | 0/29 (0%) | 17/29 (58.6%) |
| Treatment D: PF-07104091 Tablet Formulation D (Fasted) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Treatment E: PF-07104091 Tablet Formulation C (Fed) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Event | Treatment A: PF-07104091 Tablet Formulation A (Fasted) | Treatment B: PF-07104091 Tablet Formulation B (Fasted) | Treatment C: PF-07104091 Tablet Formulation C (Fasted) | Treatment D: PF-07104091 Tablet Formulation D (Fasted) | Treatment E: PF-07104091 Tablet Formulation C (Fed) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 18/20 | 14/30 | 13/29 | 4/15 | 1/14 |
| VomitingGastrointestinal disorders | 6/29 | 7/30 | 3/29 | 3/15 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 5/29 | 4/30 | 5/29 | 1/15 | 0/14 |
| HeadacheNervous system disorders | 3/29 | 5/30 | 3/29 | 2/15 | 0/14 |
| DyspepsiaGastrointestinal disorders | 0/29 | 1/30 | 0/29 | 2/15 | 0/14 |
| FatigueGeneral disorders | 1/29 | 1/30 | 3/29 | 1/15 | 0/14 |
| DizzinessNervous system disorders | 3/29 | 1/30 | 3/29 | 1/15 | 1/14 |
| PainGeneral disorders | 0/29 | 0/30 | 0/29 | 0/15 | 1/14 |
| Appetite disorderMetabolism and nutrition disorders | 0/20 | 0/30 | 0/29 | 0/15 | 1/14 |
| Rash erythematousSkin and subcutaneous tissue disorders | 0/29 | 0/30 | 1/29 | 0/15 | 1/14 |
All enrolled participants were analyzed.
| Age, Continuous(Years) | Treatment Sequence ABCD+BCAD+CABD | Treatment Sequence ABCE+BCAE+CABE | Total |
|---|---|---|---|
| Mean | 41.9 ± 13.04 | 40.3 ± 13.06 | 41.1 ± 12.85 |
| Sex: Female, Male(Participants) | Treatment Sequence ABCD+BCAD+CABD | Treatment Sequence ABCE+BCAE+CABE | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 15 | 15 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence ABCD+BCAD+CABD | Treatment Sequence ABCE+BCAE+CABE | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 7 |
| Not Hispanic or Latino | 13 | 10 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence ABCD+BCAD+CABD | Treatment Sequence ABCE+BCAE+CABE | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 8 | 14 |
| White | 6 | 7 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2022 to primary completion in Oct 2022, 4 months.
Results were first posted in Apr 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.